Lorenzo Galluzzi

Ca Fluxes and Cancer.

Classification of current anticancer immunotherapies.

Aberrant ketolysis fuels hepatocellular cancer progression.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.

Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.

Necroptosis: Mechanisms and Relevance to Disease.

Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.

Immunosuppressive T cells foster pancreatic carcinogenesis.

Involvement of autophagy in NK cell development and function.

Calreticulin and type I interferon: An unsuspected connection.

Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.

Autophagy in natural and therapy-driven anticancer immunosurveillance.

An epigenetic modifier triggers therapeutic immune responses against breast cancer.

Novel immune checkpoint blocker to treat Merkel cell carcinoma.

Trial watch: Dendritic cell-based anticancer immunotherapy.

PD-L1 blockade for urothelial carcinoma.

Immune recognition of irradiated cancer cells.

Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade.

CD103 cells at the forefront of anticancer immunity.

Blinatumomab bridges the gap between leukemia and immunity.

Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Trial watch: Immune checkpoint blockers for cancer therapy.

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

CARs on a highway with roadblocks.

Trial watch: DNA-based vaccines for oncological indications.

Mitochondrial metabolism and cancer.

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Lysosome-targeting agents in cancer therapy.

Guidelines and recommendations on yeast cell death nomenclature.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Oncogene-induced senescence and tumour control in complex biological systems.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Modeling Tumor Immunology and Immunotherapy in Mice.

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.

Cytosolic DNA Sensing in Organismal Tumor Control.

WNT Signaling in Cancer Immunosurveillance.

The hallmarks of successful anticancer immunotherapy.

Linking cellular stress responses to systemic homeostasis.

Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca levels and tumor growth.

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Trial watch: Peptide-based vaccines in anticancer therapy.

Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Potent immunosuppressive effects of the oncometabolite -2-hydroxyglutarate.

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

T Cells: Friends and Foes.

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy.

Etiological involvement of CFTR in apparently unrelated human diseases.

Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity.

Born to Kill: NK Cells Go to War against Cancer.

Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity.

Cancer Cells Thrive on Stress.

Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate.

Stress responses in stromal cells and tumor homeostasis.

Metabolic enzymes expressed by cancer cells impact the immune infiltrate.

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Trial watch: dietary interventions for cancer therapy.

Heterogeneous cellular effects of α-ketoglutarate esters.

Autophagy-Independent Functions of the Autophagy Machinery.

Macrophages and Metabolism in the Tumor Microenvironment.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy.

Extracorporeal photochemotherapy induces bona fide immunogenic cell death.

Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients.

Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity.

Drugging cancer metabolism: Expectations vs. reality.

Methods to Detect Immunogenic Cell Death In Vivo.

Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles.

Today's Special on the Anticancer Menu: Immunomodulation by Antifolates.

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.

Trial watch: dendritic cell vaccination for cancer immunotherapy.

Apoptotic caspases cut down the immunogenicity of radiation.

Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients.

Correction to: Methods to Detect Immunogenic Cell Death In Vivo.

Preface: More than two decades of modern tumor immunology.

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients.

Preface: Dendritic cells: Master regulators of innate and adaptive immunity.

Preface-Dendritic cells: Master regulators of innate and adaptive immunity.

Targeting Mutant KRAS for Immunogenic Cell Death Induction.

Autophagy in hepatic adaptation to stress.

Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.

Preface: More than two decades of modern tumor immunology.

Preface: More than two decades of modern tumor immunology.

Calreticulin arms NK cells against leukemia.

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.

Monitoring abscopal responses to radiation in mice.

Preface: More than two decades of modern tumor immunology.

Preface: Endoplasmic reticulum in health and disease.

Preface: More than two decades of modern tumor immunology.

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.

Immunogenic Cell Death Driven by Radiation-Impact on the Tumor Microenvironment.

Preface: Life through death-Key role of cellular suicide for colonial and organismal homeostasis.

Immunogenicity of cell death driven by immune effectors.

Transient Autophagy Inhibition Precipitates Oncogenesis: A Red Flag For Pharmacological Autophagy Inhibitors?

Noncanonical Cell Fate Regulation by Bcl-2 Proteins.

Preface: Life through death-Key role of cellular suicide for colonial and organismal homeostasis.

Immunomodulation by anticancer cell cycle inhibitors.

Cancer Immunotherapy with CDK7 Inhibitors.

Preface: Life through death-Key role of cellular suicide for colonial and organismal homeostasis.

Possible mechanisms of cancer prevention by nicotinamide.

Preface-Autophagy: An old mechanism with new challenges ahead.

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.

Calreticulin and cancer.

Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy.

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.

Caspase 2 and p53 Reunited in Tumor Control.

Mitochondrial control of innate immune signaling by irradiated cancer cells.

NK cells beat T cells at early breast cancer control.

Trial watch: TLR3 agonists in cancer therapy.

Trial watch: STING agonists in cancer therapy.

Trial watch: IDO inhibitors in cancer therapy.

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.

Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression.

Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.

Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.

Senescence Inflames the Pancreatic Tumor Microenvironment.

Detection of immunogenic cell death and its relevance for cancer therapy.

Autophagy in the cancer-immunity dialogue.

Immunomodulation by targeted anticancer agents.

Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.

Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.

Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control.

Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer.

Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy.

Exogenous and endogenous sources of serine contribute to colon cancer metabolism, growth, and resistance to 5-fluorouracil.

Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy.

Preface - Extracellular vesicles: An exciting and rapidly expanding field of investigation.

Oncosuppressive functions of PIDD1 in response to centrosome amplification.

Intratumoral heterogeneity in cancer progression and response to immunotherapy.

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).

Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.

Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents.

Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery.

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.

Targeting replication stress to tackle cancer stem cells.

MPA/DMBA-driven mammary carcinomas.

Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons.

A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients.

Could Protons Promote Tumor Control by Avoiding Lymphopenia?

Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells.

Immunology of Cell Death in Cancer Immunotherapy.

ATP and cancer immunosurveillance.

Immunological barriers to immunotherapy in primary and metastatic breast cancer.

Targeting Serine in Cancer: Is Two Better Than One?

Vesicular trafficking in cellular responses to stress.

Preface: Ca in health and disease.

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.

Vesicular trafficking in cellular responses to stress.

Ca in health and disease.

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.

Autophagy in major human diseases.

Chromatin and genomic instability in cancer.

Immunological configuration of ovarian carcinoma: features and impact on disease outcome.

Control of host mitochondria by bacterial pathogens.

Trial watch: intratumoral immunotherapy.

Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives.

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma.

MDSCs sneak CSCs out of (immuno)surveillance.

Using epigenetic modifiers to target cancer stem cell immunoevasion.

Immunogenic cell stress and death.

Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives.

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.

Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Immunostimulatory effects of radioimmunotherapy.

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.

Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.

BAX and BAK dynamics control mitochondrial DNA release during apoptosis.

Restored Ketosis Drives Anticancer Immunity in Colorectal Cancer.

Myeloid-Derived Suppressor Cells and Radiotherapy.

A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients.

Catastrophic DNA replication in unscheduled tetraploid cells.

Developing antisense oligonucleotides for a mutation-induced, ultra-rare neurological disorder using patient-derived cellular models.

Mitochondrial control of inflammation.

Immuno-epigenetic escape of cancer stem cells.

Cytofluorometric assessment of cell cycle progression in irradiated cells.

Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis.

RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells.

Cytofluorometric assessment of acute cell death responses driven by radiation therapy.

Radiation therapy: An old dog learning new tricks.

Adaptation to MOMP drives cancer persistence.

Emergent impact of lifestyle on tumor progression and response to therapy.

Calreticulin surface presentation can promote quality control of hematopoietic stem cells.

NK cells and solid tumors: therapeutic potential and persisting obstacles.

T cell-independent abscopal responses to radiotherapy.

Meta-hallmarks of aging and cancer.

Quantitative assessment of mitophagy in irradiated cancer cells.

Cellular senescence in the response of HR breast cancer to radiotherapy and CDK4/6 inhibitors.

Immunogenic cell death in cancer: concept and therapeutic implications.

p53 regulates the mitochondrial immune checkpoint.

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.

Myeloid-derived suppressor cells: Emerging players in cancer and beyond.

The DNA Damage Response and Inflammation in Cancer.

Radiation therapy: An old dog learning new tricks.

Epigenetic escape of immunosurveillance by malignant cell precursors.

Apoptotic cell death in disease-Current understanding of the NCCD 2023.

Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia.

Immunologically relevant effects of radiation therapy on the tumor microenvironment.

Calreticulin exposure orchestrates innate immunosurveillance.

Ca signaling and cell death.

Emerging evidence for adapting radiotherapy to immunotherapy.

Cell death and senescence.

Dual impact of radiation therapy on tumor-targeting immune responses.

A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.

Cancer stem cell immunoediting by IFNγ.

Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.

BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.

Interferon signaling restrains renal cell carcinoma heterogeneity.

Type I interferon and cancer.

Molecular determinants of immunogenic cell death elicited by radiation therapy.

Chromosomal instability drives immunosuppression and metastatic dissemination.

A mitochondrial checkpoint to adaptive anticancer immunity.

Immunosurveillance in clinical cancer management.

Mitochondrial control of antigen presentation in cancer cells.

Radiation therapy: An old dog learning new tricks.

Bacterial antigens unleash tumor-targeting immunity.

Non-mutational neoantigens in disease.

Cellular senescence and aging at the crossroad between immunity and cancer.

Immunogenicity of ferroptosis in cancer: a matter of context?

A guideline on the molecular ecosystem regulating ferroptosis.

International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis.

Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.

LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells.

Preface.